Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 5:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 52 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cholinergic System Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

The Nicotinic Cholinergic System and Cognitive Aging

NCT03408574
View directory record Official record
Conditions
Healthy Aging
Interventions
Nicotine patch, oral mecamylamine, placebo
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years to 75 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated May 8, 2023 · Synced Jul 21, 2026, 5:29 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Cholinergic Integrity in Down Syndrome in Association With Aging, Alzheimer's Disease Pathology, and Cognition

NCT05231798
View directory record Official record
Conditions
Down Syndrome, Down Syndrome, Partial Trisomy 21, Alzheimer Disease
Interventions
[18F]-FEOBV Radiotracer
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Jul 21, 2026, 5:29 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines

NCT05976243
View directory record Official record
Conditions
Chronic Inducible Urticaria
Interventions
Remibrutinib, Placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
25
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Bakersfield, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Jul 21, 2026, 5:29 PM EDT
Completed Phase 2 Interventional Results available

Effects of Cholinergic Augmentation on Measures of Balance and Gait

NCT02206620
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Donepezil
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
30 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Jul 21, 2026, 5:29 PM EDT
Recruiting No phase listed Observational

Striatal and Extra-Striatal Cholinergic Terminal Density in LRRK2-PD Mutation

NCT07642908
View directory record Official record
Conditions
Parkinson Disease
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
45 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Jul 21, 2026, 5:29 PM EDT
Not yet recruiting Early Phase 1 Interventional Accepts healthy volunteers

Cholinergic Enhancement of Theta

NCT07228338
View directory record Official record
Conditions
Epilepsy, Seizures, Cognitive Impairment, Mild, Memory Disorder, Memory Loss
Interventions
COBENFY KarXT (50/20 mg), Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Jul 21, 2026, 5:29 PM EDT
Recruiting Not applicable Interventional

Ultrasound Neuroimmune Modulation in Adults With Rheumatoid Arthritis

NCT07293871
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Active treatment, Sham (No Treatment)
Device
Lead sponsor
Surf Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Colleyville, Texas • Dallas, Texas • Irving, Texas
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Jul 21, 2026, 5:29 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Brain Imaging in Elderly People and Individuals With Alzheimer's Disease

NCT00001917
View directory record Official record
Conditions
Alzheimer's Disease, Healthy
Interventions
O15, [F-18] FP-TZTP
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 21, 2026, 5:29 PM EDT
Completed No phase listed Observational Results available

Amyloidopathy, Cholinopathy, Dopamine Responsiveness and Freezing of Gait in PD

NCT03647137
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Detailed motor testing, including FoG, in PD subjects
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 4, 2024 · Synced Jul 21, 2026, 5:29 PM EDT
Completed Phase 2 Interventional

A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia

NCT07038876
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, ML-007C-MA BID, ML-007C-MA QD
Drug
Lead sponsor
MapLight Therapeutics
Industry
Eligibility
18 Years to 64 Years
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
24
States / cities
Little Rock, Arkansas • Bellflower, California • Culver City, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Jul 21, 2026, 5:29 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cholinergic Nicotinic Receptors and Cognition in PD

NCT02076295
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
50 Years and older
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 16, 2017 · Synced Jul 21, 2026, 5:29 PM EDT
Completed Phase 4 Interventional

Cholinergic Neurotransmission in Mobility and Cognition in Parkinson Disease

NCT03840837
View directory record Official record
Conditions
Parkinson Disease, Parkinson Disease Dementia
Interventions
Rivastigmine transdermal patch
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Jul 21, 2026, 5:29 PM EDT
Not listed Phase 3 Interventional

Independent Studies of Dextromethorphan and of Donepezil Hydrochloride for Rett Syndrome

NCT00069550
View directory record Official record
Conditions
Rett Syndrome
Interventions
dextromethorphan, donepezil hydrochloride
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
1 Year to 15 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 21, 2026, 5:29 PM EDT
Completed No phase listed Observational

Decrease in Sense of Smell and Associated Cognitive Decline in Parkinson's Disease

NCT01572142
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
50 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 28, 2017 · Synced Jul 21, 2026, 5:29 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Mental Ability Challenge Study in Adults With and Without HIV

NCT03244488
View directory record Official record
Conditions
HIV-1-infection, Aging, Premature, Cognitive Impairment, Memory Impairment, HIV-Associated Cognitive Motor Complex
Interventions
Scopolamine Injectable Product, Mecamylamine Pill
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
35 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 24, 2019 · Synced Jul 21, 2026, 5:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Sublingual Atropine Bioequivalence by Route of Administration (SABER)

NCT06366087
View directory record Official record
Conditions
Atropine Bioequivalence
Interventions
Atropine Sulfate Ophthalmic Solution USP, 1%, Atropine Sulfate Injection, USP 8 mg/20 mL (0.4 mg/mL)
Drug
Lead sponsor
Biomedical Advanced Research and Development Authority
Federal
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Jul 21, 2026, 5:29 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease

NCT02458430
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
50 Years to 99 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 1, 2021 · Synced Jul 21, 2026, 5:29 PM EDT
Enrolling by invitation Not applicable Interventional

Cholinergic Deep Brain Stimulation for Alzheimer's Disease

NCT05882344
View directory record Official record
Conditions
Alzheimer Disease, Early Onset, Dementia, Alzheimer Disease
Interventions
Device Implantation- Boston Scientific, VERCISE GENUS™ system, DBS Stimulation - Boston Scientific, VERCISE GENUS™ system
Procedure · Device
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
60 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Jul 21, 2026, 5:29 PM EDT
Recruiting Phase 2 Interventional

A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia

NCT07459647
View directory record Official record
Conditions
Schizophrenia
Interventions
ML-007C-MA
Drug
Lead sponsor
MapLight Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
5
States / cities
Lemon Grove, California • Miami Lakes, Florida • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Jul 21, 2026, 5:29 PM EDT
Completed Phase 3 Interventional

Investigation Into Delay to Diagnosis of Alzheimer's Disease With Exelon (InDDEx)

NCT00000174
View directory record Official record
Conditions
Alzheimer Disease, Cognition Disorders
Interventions
Rivastigmine
Drug
Lead sponsor
Novartis
Industry
Eligibility
55 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
15
States / cities
Peoria, Arizona • Orange, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 21, 2026, 5:29 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Effects of Acetylcholine and Attention on Visual Spatial Representations in the Brain

NCT05003063
View directory record Official record
Conditions
Visual Perception, Attention, Information Processing, Cholinergic System
Interventions
Donepzil, Placebo oral tablet
Drug
Lead sponsor
University of California, Berkeley
Other
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2021 · Synced Jul 21, 2026, 5:29 PM EDT
Terminated Phase 2 Interventional Results available

Transcutaneous Cervical Vagus Nerve Stimulation (tcVNS) in JIA

NCT05710640
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis (JIA)
Interventions
Active tcVNS, Sham tcVNS
Device
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
5 Years to 18 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
7
States / cities
San Francisco, California • Orlando, Florida • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Jul 21, 2026, 5:29 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Cholinergic Health After Menopause (CHAMP)

NCT04129060
View directory record Official record
Conditions
Postmenopausal Symptoms, Aging, Alzheimer Disease
Interventions
Cholinergic antagonist
Drug
Lead sponsor
University of Vermont
Other
Eligibility
50 Years to 70 Years · Female only
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
2
States / cities
Nashville, Tennessee • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jul 21, 2026, 5:29 PM EDT
Completed Phase 2 Interventional Results available

Crossover Target Engagement Study of Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease (Project #3 - Experiment 3 [UdallP3E3])

NCT04403399
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Varenicline, Placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
45 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Jul 21, 2026, 5:29 PM EDT